Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.

3.7 months, respectively), and a positive trend in median PFS [ 62 ]; however, all the results were not statistically significant, possibly due to a small number of patients and statistical bias of the analysis.

also in 11,005 other papers

In 2011 in a randomized phase II trial was evaluated the activity of the combination of Tivantinib (ARQ197), a highly selective MET TKI, with erlotinib versus erlotinib plus placebo in advanced NSCLC patients, at progression on first-line chemotherapy [ 35 ]; results showed a trend in favor of the experimental arm in terms of median PFS, which was the primary endpoint of the study (3.8 months for tivantinib vs. 2.3 months for the placebo, HR = 0.81, p = 0.24), although not statistically significant.

also in 53,322 other papers